Corbus Pharmaceuticals Holdings Inc. [CRBP] stock Initiated by ROTH Capital analyst, price target now $40

Corbus Pharmaceuticals Holdings Inc. [NASDAQ: CRBP] price plunged by -11.47 percent to reach at -$0.82. The company report on August 6, 2020 that Corbus Pharmaceuticals Reports Second Quarter Financial Results and Corporate Updates.

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative medicines that target the endocannabinoid system, today reported financial results for the second quarter of 2020. The Company also provided clinical and corporate updates.

“We had a busy second quarter as we prepare for a potentially transformative second half of the year with two expected data readouts, including topline data in our Phase 3 study for systemic sclerosis this summer, followed by our Phase 2b study in cystic fibrosis. We recently announced that we completed sales of $71 million through our ATM program and entered a debt financing agreement for up to $50 million with the first $20 million already received, strengthening our balance sheet and putting us in a solid financial position before topline data,” said Yuval Cohen, Ph.D., Chief Executive Officer. “We have also appointed a new board member, Dr. George Golumbeski who brings considerable expertise in corporate and business development. With these recent updates, a strong balance sheet and the critical data readouts now closer than ever, we continue to prepare the groundwork for NDA submission and commercialization following potential FDA approval.”.

A sum of 2787985 shares traded at recent session while its average daily volume was at 1.55M shares. Corbus Pharmaceuticals Holdings Inc. shares reached a high of $7.23 and dropped to a low of $6.26 until finishing in the latest session at $6.33.

Guru’s Opinion on Corbus Pharmaceuticals Holdings Inc. [CRBP]:

ROTH Capital have made an estimate for Corbus Pharmaceuticals Holdings Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on July 07, 2020. While these analysts kept the previous recommendation, BTIG Research raised their target price to Buy. The new note on the price target was released on June 17, 2020, representing the official price target for Corbus Pharmaceuticals Holdings Inc. stock. Previously, the target price had yet another raise to $12, while Nomura analysts kept a Buy rating on CRBP stock.

The Average True Range (ATR) for Corbus Pharmaceuticals Holdings Inc. is set at 0.48, with the Price to Sales ratio for CRBP stock in the period of the last 12 months amounting to 13.56. The Price to Book ratio for the last quarter was 19.18, with the Price to Cash per share for the same quarter was set at 0.60.

CRBP Stock Performance Analysis:

Corbus Pharmaceuticals Holdings Inc. [CRBP] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -5.10. With this latest performance, CRBP shares dropped by -20.28% in over the last four-week period, additionally sinking by -7.73% over the last 6 months – not to mention a rise of 11.05% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for CRBP stock in for the last two-week period is set at 41.18, with the RSI for the last a single of trading hit 38.86, and the three-weeks RSI is set at 42.22 for Corbus Pharmaceuticals Holdings Inc. [CRBP]. The present Moving Average for the last 50 days of trading for this stock 7.30, while it was recorded at 6.68 for the last single week of trading, and 6.01 for the last 200 days.

Insight into Corbus Pharmaceuticals Holdings Inc. Fundamentals:

Operating Margin for any stock indicates how profitable investing would be, and Corbus Pharmaceuticals Holdings Inc. [CRBP] shares currently have an operating margin of -226.01. Corbus Pharmaceuticals Holdings Inc.’s Net Margin is presently recorded at -197.69.

Return on Total Capital for CRBP is now -375.38, given the latest momentum, and Return on Invested Capital for the company is -342.06. Return on Equity for this stock declined to -424.29, with Return on Assets sitting at -148.66. When it comes to the capital structure of this company, Corbus Pharmaceuticals Holdings Inc. [CRBP] has a Total Debt to Total Equity ratio set at 153.40. Additionally, CRBP Total Debt to Total Capital is recorded at 60.54, with Total Debt to Total Assets ending up at 19.22. Long-Term Debt to Equity for the company is recorded at 131.50, with the Long-Term Debt to Total Capital now at 51.89.

Reflecting on the efficiency of the workforce at the company, Corbus Pharmaceuticals Holdings Inc. [CRBP] managed to generate an average of -$506,764 per employee. Receivables Turnover for the company is 26.96 with a Total Asset Turnover recorded at a value of 0.75.Corbus Pharmaceuticals Holdings Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.60 and a Current Ratio set at 1.60.


With the latest financial reports released by the company, Corbus Pharmaceuticals Holdings Inc. posted -0.32/share EPS, while the average EPS was predicted by analysts to be reported at -0.38/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 15.80%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for CRBP.

Corbus Pharmaceuticals Holdings Inc. [CRBP] Insider Position Details

There are presently around $226 million, or 51.10% of CRBP stock, in the hands of institutional investors. The top three institutional holders of CRBP stocks are: BLACKROCK INC. with ownership of 5,772,447, which is approximately 6.656% of the company’s market cap and around 0.50% of the total institutional ownership; KNOLL CAPITAL MANAGEMENT, LP, holding 5,045,870 shares of the stock with an approximate value of $31.94 million in CRBP stocks shares; and ETF MANAGERS GROUP, LLC, currently with $22.59 million in CRBP stock with ownership of nearly -38.26% of the company’s market capitalization.

Positions in Corbus Pharmaceuticals Holdings Inc. stocks held by institutional investors increased at the end of August and at the time of the August reporting period, where 75 institutional holders increased their position in Corbus Pharmaceuticals Holdings Inc. [NASDAQ:CRBP] by around 7,943,413 shares. Additionally, 31 investors decreased positions by around 3,053,499 shares, while 26 investors held positions by with 24,709,427 shares. The mentioned changes placed institutional holdings at 35,706,339 shares, according to the latest SEC report filing. CRBP stock had 30 new institutional investments in for a total of 3,139,888 shares, while 12 institutional investors sold positions of 412,867 shares during the same period.

Share on facebook
Share on twitter
Share on linkedin
Share on skype
Share on reddit

Leave a Comment

Your email address will not be published. Required fields are marked *

Get The Best Stocks To Trade Every Day!

Join now to get the pre-market morning brief 100% free

We do not sell or share your information with anyone.

Get Notified Of Insider Trades, Analyst Upgrades & Downgrades, Earnings Updates & Best Stocks To Trade Every Single Morning

100% free. stop anytime no spam